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Abstract
Endocannabinoids (ECs) are involved in immunomodulation, neuroprotection and control of
inflammation in the central nervous system (CNS). Activation of cannabinoid type 2 recep-
tors (CB2) is known to diminish the release of pro-inflammatory factors and enhance the
secretion of anti-inflammatory cytokines. Furthermore, the endocannabinoid 2-arachidonoyl
glycerol (2-AG) has been proved to induce the migration of eosinophils in a CB2 receptor-
dependent manner in peripheral blood and activate neutrophils independent of CB activation
in humans. The aim of the current study was to investigate the influence of the endocannabi-
noid system in two different CNS inflammatory diseases of the dog, i.e. Steroid-Responsive
Meningitis-Arteritis (SRMA) and Intraspinal Spirocercosis (IS). The two main endocannabi-
noids, anandamide (AEA) and 2-AG, were quantified by mass spectrometry in CSF and
serum samples of dogs affected with Steroid- Responsive Meningitis-Arteritis in the acute
phase (SRMA A), SRMA under treatment with prednisolone (SRMA Tr), intraspinal Spiro-
cercosis and healthy dogs. Moreover, expression of the CB2 receptor was evaluated in
inflammatory lesions of SRMA and IS and compared to healthy controls using immunohis-
tochemistry (IHC). Dogs with SRMA A showed significantly higher concentrations of total
AG and AEA in serum in comparison to healthy controls and in CSF compared to SRMA Tr
(p<0.05). Furthermore, dogs with IS displayed the highest ECs concentrations in CSF,
being significantly higher than in CSF samples of dogs with SRMA A (p<0.05). CSF samples
that demonstrated an eosinophilic pleocytosis had the highest levels of ECs, exceeding
those with neutrophilic pleocytosis, suggesting that ECs have a major effect on migration
of eosinophils in the CSF. Furthermore, CB2 receptor expression was found in glial cells in
the spinal cord of healthy dogs, whereas in dogs with SRMA and IS, CB2 was strongly
expressed not only in glial cells but also on the cellular surface of infiltrating leukocytes (i.e.
neutrophils, eosinophils, lymphocytes, plasma cells, and macrophages) at lesion sites. The
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present study revealed an upregulated endocannabinoid system in dogs with inflammatory
CNS diseases, highlighting the endocannabinoid system as a potential target for treatment
of inflammatory CNS diseases.
Introduction
In the last decades an increasing interest emerged in the use of derivatives of the plant Canna-
bis sativa and Cannabis indica commonly known as Marijuana to treat a variety of disorders
both in humans and animals. One of the main reasons for such an effort is that numerous can-
nabinoids have potential medicinal effects lacking the psychoactive effects of some phytocan-
nabinoids like Δ9–tetrahydrocannabinol (THC) [1, 2]. These compounds interact mainly with
two receptors, cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2),
which are expressed in several tissues in mammals [3] and together with their endogenous
ligands (endocannabinoids) and the enzymes responsible for their synthesis and degradation
constitute the endocannabinoid system [4, 5].
Endocannabinoids (ECs) are endogenous lipid transmitters that mimic the action of THC
by binding and activating the cannabinoid receptors [6]. The most bioactive ECs and the best
studied ones are Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) [4, 6, 7]. Ananda-
mide was firstly identified in the porcine brain as an endogenous ligand of the CB1 receptor
[8], and shows low affinity to CB2 receptors [9]. 2-AG was isolated from canine intestine,
being the first endocannabinoid isolated from peripheral tissue [10]. However, 2-AG was also
isolated from the rat brain [11]. Endocannabinoids bind to local receptors only and are imme-
diately inactivated under physiological conditions [12].
CB1 receptors are expressed mostly on neurons [13] and mediate the inhibition of neuro-
transmitter release [3], while CB2 receptors are highly expressed on immune cells [14] modu-
lating cytokine release [3], decreasing antigen presentation [15] and modulating cell migration
[1]. As a result, many of the medicinal properties of cannabinoid compounds have been attrib-
uted to the CB2 receptor, especially those related to immune system modulation [1]. In dogs,
CB2 receptors have been identified in Although CB2 receptors are not strongly expressed in
the brain under normal conditions, in neuroinflammatory diseases an up-regulation occurs in
microglial and glial cells [16] allowing the endocannabinoid system to function as an immune
modulator in both the peripheral immune system as well as the central nervous system (CNS)
[17].
Increasing evidence supports the immunomodulatory roles of 2-AG and AEA [18]. More-
over, exogenous application of 2-AG and AEA has shown to exert anti-inflammatory effects by
decreasing the production of inflammatory mediators [19]. The anti-inflammatory and neuro-
protective effects of endocannabinoids and cannabinoids have been shown in several experi-
mental models [20–26], where activation of the endocannabinoid system has been linked to
decreased inflammatory cell recruitment and enhanced anti-inflammatory cytokine produc-
tion [18]. Therefore, the endocannabinoid system could be established as a promising target
for the treatment of inflammatory disorders.
The aim of the current study was to investigate in a comparative way the influence of the
endocannabinoid system in two different inflammatory CNS diseases of the dog, i.e. SRMA
and IS. SRMA is a systemic immune disorder characterized by inflammatory lesions of vessels,
particularly in the cervical leptomeninges [27]. Spirocerca Lupi is a nematode parasite of dogs
and other carnivores which affects mainly the esophagus and aorta [28] and aberrant migra-
tion to the spinal cord parenchyma has been previously reported [29, 30]. The following
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hypotheses should be proven: (i) endocannabinoids can be measured in cerebrospinal fluid
(CSF) in inflammatory diseases; (ii) the endocannabinoid system depends on the etiology of
the inflammatory CNS disease and might influence the differential cell count of CSF; (iii) CB2
receptors are up-regulated in inflammatory lesions of SRMA and IS. For this purpose, the
endocannabinoids, AEA and 2-AG were measured in CSF and serum samples by mass spec-
trometry and CB2 receptor expression was evaluated in inflammatory lesions in the spinal
cord of dogs with SRMA and IS using routine immunohistochemistry.
Materials and methods
Serum and cerebrospinal fluid samples
A total of 41 cerebrospinal fluid (CSF) samples and 36 serum samples were retrospectively ana-
lyzed. From them, 27 paired serum and CSF samples were collected between July 2008 and
December 2012 from client-owned dogs diagnosed with SRMA at the Department of Small
Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Germany. Addi-
tionally, 3 serum and 7 CSF samples from seven dogs affected with IS presented to the Koret
School of Veterinary Medicine Teaching hospital, The Hebrew University of Jerusalem, Israel.
Finally, 6 paired CSF and serum samples from healthy Beagles from the Department of Small
Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Germany, were
used as controls. This study was conducted in accordance with the ethical guidelines of the
University of Veterinary Medicine Hannover and was approved by the authorities of Lower
Saxony (Animal experiment number 33.9-42502-05-12A214). CSF samples were collected
from the cerebellomedullary cistern or lumbar subarachnoidal space of the dogs under general
anaesthesia, and serum samples were obtained by puncture of the cephalic or saphenous
peripheral vein. Routine CSF analysis was performed immediately after collection and the
remaining CSF and serum samples were stored at -20˚C until further analysis.
SRMA in the acute stage (SRMA A) was defined by occurrence of cervical rigidity and pain,
fever and polymorphonuclear pleocytosis in the CSF [31]. Other possible causes of neck pain,
elevated temperature and/or pleocytosis in CSF were ruled out. Dogs in SRMA A group were
not pre-treated with glucocorticosteroids prior to CSF puncture. On the other hand, dogs in
the SRMA treatment (Tr) group were under long-term treatment with prednisolone as previ-
ously described [32] and did not show any clinical signs at the time of sampling. Furthermore,
they displayed routine CSF parameters in physiological ranges (cell count: 0–3 cells/μl; glucose
60–80% of the blood glucose concentration; protein < 25 mg/dl) [33].
Inclusion criteria for IS required dogs to live in areas endemic for Spirocerca Lupi and the
combination of the following characteristic clinical and pathological findings: acute onset of
non-symmetrical hind limb paralysis, radiographic or endoscopic evidences of esophageal
granuloma and eosinophilic pleocytosis. Favorable response to treatment supported the diag-
nosis in dogs that survived and detection of the nematode within the spinal cord parenchyma
confirmed the diagnosis in dogs that were euthanized due to lack of improvement.
Serum and CSF samples were used for determination of both endocannabinoids (AEA and
2-AG) by stable-isotope dilution liquid chromatography combined with tandem mass spec-
trometry (LC-MS/MS) [34, 35].
Animals and tissue samples
A total of 8 dogs with SRMA, 2 dogs with confirmed IS, and 5 healthy controls were included
in the immunohistochemical evaluation. The healthy control group consisted of 5 Beagles
without clinical or pathological evidence of neurologic or infectious diseases. Tissue samples
were obtained following routine necropsy and were included in previous studies [36, 37]
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conducted in accordance with the German Animal Welfare Act with the law of animal welfare,
Germany (permission number: 33.9-42502-05-13A346), and following the ethical guidelines
of the University of Veterinary Medicine Hannover. No animals were euthanized for this par-
ticular study; samples obtained and previously used in other studies were taken. The study
wasapproved and followed the guidelines of the PhD commission of the University ofVeterin-
ary Medicine Hannover, the institutional ethics committee.
Spinal cord tissue samples from six of the 8 dogs with SRMA originated from the Depart-
ment of Clinical Research and Veterinary Public Health, Vetsuisse University of Bern Switzer-
land, and two were obtained from the Department of Pathology, University of Veterinary
Medicine Hannover, Germany. Tissue samples from dogs with confirmed intraspinal migra-
tion of Spirocerca Lupi were sent from Korea School of Veterinary Medicine, The Hebrew Uni-
versity of Jerusalem, Israel.
Sections of the cervical, thoracic, and lumbar spinal cord were collected during necropsy
and fixed in 10% formalin for at least 24 hours. After fixation, tissue samples were embedded
in paraffin, cut at serial sections (3 μm), mounted onto coated slides (SuperFrost-Plus1 slides;
Menzel Gla¨ser, Braunschweig, Germany), and stained with hematoxylin and eosin (HE). Sub-
sequently, a complete histological examination in order to detect histopathological lesions and
immunohistochemical staining to evaluate CB2 expression were performed. Given the fact
that CB2 receptors are strongly expressed in immune tissues and leukocyte subpopulations
[14], spleen and liver tissue of a healthy dog served as positive control and was processed
equally.
Details of breed, sex, age, and morphological changes of the lesions and diagnosis from all
dogs are summarized in Table 1.
Table 1. Sex, age, anatomic localization of the lesions, morphological diagnosis in dogs suffering SRMA, IS and control dogs.
Case Breed Sex Age Spinal cord section analyzed Morphological changes in spinal cord Diagnosis
Vasculitis Meningitis Hemorrhage Myelomalacia
1 Beagle M 6m Cervical - - - - Healthy
(Control dog)
2 Beagle M 6m Cervical - - - - Healthy
(Control dog)
3 Beagle M 6m Cervical - - - - Healthy
(Control dog)
4 Beagle F 6m Cervical - - - - Healthy
(Control dog)
5 Beagle F 6m Cervical - - - - Healthy
(Control dog)
6 Great Dane M 5y, 10m Cervical, thoracic, lumbar ++ ++ - + SRMA
7 Mixed breed M 8m Cervical +++ +++ +++ +++ SRMA
8 Tibetan Terrier M 1y Cervical +++ +++ ++ +++ SRMA
9 n-a F 7m Cervical, thoracic, lumbar ++ ++ - - SRMA
10 Newfoundland F n-a Thoracic ++ ++ - - SRMA
11 Bernese Mountain Dog F n-a Cervical, thoracic, lumbar +++ +++ ++ - SRMA
12 Labrador Retriever mix M 6y Cervical +++ ++ + - SRMA
13 German Shepherd M 10m Cervical, thoracic, lumbar +++ +++ - - SRMA
14 Golden Retriever F 4y Thoracic, lumbar + ++ +++ +++ Intraspinal Spirocercosis
15 Mixed breed F n-a Thoracic + + +++ +++ Intraspinal Spirocercosis
CNS: Central Nervous System; SRMA: steroid-responsive meningitis-arteritis; IS: intraspinal spirocercosis; y: years; m: months; n-a: not available; M: male; F: female;
absent: -; mild: +; moderate: ++; severe: +++.
https://doi.org/10.1371/journal.pone.0187197.t001
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Liquid chromatography combined with tandem mass spectrometry
(LC-MS/MS)
The quantification of AEA and 2-AG in CSF and serum samples was performed by stable-iso-
tope dilution liquid chromatography combined with tandem mass spectrometry (LC-MS/MS)
as previously described [34, 35]. Briefly, after thawing on ice, Hydroxypropyl-β-cyclodextrine
(10% w/v) was added to CSF samples prior to liquid-liquid extraction to improve extraction
efficacy. This step was not required for serum samples. Additionally, 500 μl of the internal
standards d4-AEA (Nr. 10011178, Cayman chemical, Michigan, USA) and d5-2-AG (Nr.
36162, Cayman chemical, Michigan, USA) were added to each sample, to a final concentration
of 1.1 nM and 1.0 nM, respectively. This step was performed on ice. Subsequently, 500 μl Tolu-
ene (Nr. 244511, Sigma-Aldrich1, Steinheim, Germany) were added to each sample and
homogenization was performed by shaking twice during 20 seconds at 5000 rpm at 4˚C in a
PreCellys tissue homogenizer. After centrifugation (5 min, 4500 xg, 4˚C) the organic phase
was separated and evaporated to dryness by a gentle stream of nitrogen for approximately 50
min. Finally, 50 μl eluent (25% water and 75% methanol) were added to the residues for liquid
chromatographic analysis and 25 μl of the solution was injected into the Waters ACQUITY/
XEVO TQ-MS LC-MS/MS system (Waters, Milford, MA, USA). Chromatographic separation
took place on a Waters ACQUITY BEH C18 reversed phase column (100 mm × 2.1 mm ID,
1.7 μM particle size) [35]. The following transitions were monitored: m/z348!m/z 62 (AEA),
m/z352!m/z66 (d4-AEA), m/z 379!m/z 287 (2-AG), and m/z 384!m/z287 (d5-2-AG).
Due to the quick isomerization of 2-AG to its less biologically active form 1-arachidonoylgly-
cerol (1-AG) [38], quantification of 2-AG is difficult to accomplish [39]. The available CSF and
serum samples in the current study contained a large portion of 1-AG as compared to 2-AG.
Therefore, 2-AG was calculated and referred to as total AG concentration using the sum of the
2-AG and 1-AG peak areas in the acquired chromatograms as previously described [34].
Immunohistochemistry
Immunohistochemistry (IHC) was performed using the avidin-biotin-peroxidase complex
(ABC) method as previously described [36, 40]. Briefly, formalin-fixed paraffin-embedded sec-
tions of the selected tissue samples were dewaxed and rehydrated in a descending alcohol dilu-
tion series. Inhibition of endogenous peroxidases was performed in 85% ethanol with 0.5%
H2O2 for 30 minutes at room temperature. Slides were pre-treated with sodium-citrate buffer
(pH 6.0–6. 5) in the microwave at 800w for 20 minutes for antigenic retrieval. In order to pre-
vent non-specific binding of the antibodies, all slides were incubated with normal goat serum
(1:5 in phosphate-buffered saline [PBS]) for 20 min at room temperature. Following blocking,
slides of interest and positive controls were incubated in a moist chamber with a polyclonal
anti-CNR2/CB2 antibody (IHC-plusTM LS-A34, LSBio, LifeSpan BioSciences, Inc., Seattle,
WA, USA; dilution 1:100 in PBS containing 1% bovine serum albumin [BSA]) overnight at
4˚C. The primary antibody used cross-reacts with human, monkey and canine CB2, as the
canine CB2 sequence shares between 76 and 82% homology with rat, mouse and human CB2
[41]. As negative control, the primary antibody was substituted by rabbit serum (R4505; Sigma
Aldrich, Taufkirchen, Germany; dilution 1:3000 in PBS with 1% BSA) and incubated for the
same time period. Subsequently, a secondary biotin-labelled goat-anti-rabbit antibody (Vector
Laboratories, Burlingame, CA, USA; dilution 1:200 in PBS) was incubated on all slides for 45
minutes at room temperature, followed by incubation with ABC (VECTASTAIN-ABC Kit
Standard, PK 6100, Vector Laboratories, Burlinghame, California, USA). Finally, slides were
incubated with the chromogen diaminobezidine-tetrahydrochloride (0.05% solution, DAB,
Sigma Aldrich, Taufkirchen, Germany) and 0.03% H2O2 for 5 minutes at room temperature
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followed by a slight counterstaining with Mayer’s hemalaun, dehydration in an ascending
series of alcohol, cleaning in acetic acid-n-butylester (EBE1, Roth, Karlsruhe, Germany), and
mounting using Roti1-Histokit (Roth, Karlsruhe, Germany). Sections of tissue samples were
independently examined via light microscopy (BX51, Olympus Optical CO., Tokyo, Japan)
and representative images were acquired by use of photodocumentation software (DP72,
Olympus Optical CO., Tokyo, Japan).
Statistical analysis
Statistical analysis to quantify differences between the levels of AEA and total AG among the
groups was performed using the SAS1 software Version SAS 9.3 (SAS Inst. Inc. Cary, North
Carolina, USA). Normal distribution of the data was found after logarithmic transformation.
For descriptive statistics, measures of location and statistical dispersion were depicted as
median and range due lognormal distribution of data. Group differences of endocannabinoid
concentrations were tested using One-way-analysis of variance for independent samples fol-
lowed by the Least Significant Difference (LSD) test, a test controlling Type I comparison wise
error rate. Differences between the groups were considered significant when the correspond-
ing p-value was lesser than 0.05. Graphics from the statistical data obtained were performed
using GraphPad1 Software (GraphPad Prism, version 5, La Jolla, California, USA).
Results
AEA and total AG were analyzed in 36 serum and 41 CSF samples. The distribution of the
samples analyzed for AEA and total AG are summarized in Table 2.
The group of dogs with SRMA included 6 females (1 neutered) and 15 males (1 neutered),
ranged between 6 months and 27 months of age (median 17 months). Furthermore, this group
included 12 different breeds mostly Boxers (31.81%) and Bernese Mountain dogs (18.18%). In
some dogs with SRMA samples were taken twice, in the acute phase (SRMA A) and during
treatment (SRMA Tr). All CSF samples in SRMA A and SRMA Tr and groups were obtained
from the cerebellomedullary cistern. Dogs in the SRMA A group displayed a neutrophilic pleo-
cytosis (Median: 619 cells/3μl; range: 7–2016 cells/3μl).
Seven dogs with IS were included in the study. These dogs presented with acute onset of
either monoparesis (n = 2), paraparesis (n = 4) or paraplegia (n = 1) of the pelvic limbs, hyper-
esthesia in the lumbar (n = 2), lumbosacral (n = 1), and both cervical and lumbosacral (n = 1)
regions, proprioceptive deficits of the pelvic limbs (n = 2), fecal and urinary incontinence
(n = 2), reduced withdrawal reflex in the pelvic limbs (n = 1) and/or ataxia of all four limbs
with hypometric gait of the thoracic limbs (n = 1). Complete blood count, chemistry profile
Table 2. Number of CSF and serum samples analysed for AEA and total AG.
Groups AEA/Total AG
CSF Serum
SRMA A 9 9
SRMA Tr 19 18
Healthy 6 6
Spirocercosis 7 3
Total 41 36
AEA: Anandamide; Total AG: 1-AG (1-arachidonoylglycerol) + 2-AG (2-arachidonoylglycerol); CSF: cerebrospinal
fluid; SRMA A: steroid-responsive meningitis-arteritis in acute stage; SRMA Tr: SRMA dogs under treatment.
https://doi.org/10.1371/journal.pone.0187197.t002
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and spinal radiographs were all normal except for elevated creatinine in one dog and mild leu-
kocytosis in two dogs.
Further evaluations included serology for Toxoplasma and Neospora infection which was
negative (n = 5). CSF samples from the IS group were taken from either the cerebellomedullary
cistern or lumbar subarachnoidal space and showed mixed neutrophilic pleocytosis with mod-
erate to severe eosinophilia.
Clinical diagnosis was further supported by improvement under treatment or at postmor-
tem examination with identification of Spirocerca Lupi nematodes. Four dogs improved clini-
cally under treatment, two deteriorated progressively and the owners opted for euthanasia. At
postmortem examination a Spirocerca Lupi nematode was identified in the caudal lumbar seg-
ments of the spinal cord and a granuloma was found in the esophagus. Outcome of 1 dog is
missing.
The healthy group was represented by 6 neutered-male Beagles, 9 months old, clinical and
neurological examinations revealed no pathological findings. CSF was obtained from the cere-
bellomedullary cistern in these dogs.
AEA and total AG in CSF and serum
Levels of AEA in CSF were found in the picomolar range (pM), in serum in the nanomolar
range (nM). Concentrations of total AG in serum and CSF were expressed in the nanomolar
range (nM).
Levels of AEA in CSF and serum
The type 3 test of fixed effects denies the hypothesis of equal means of AEA for all group levels
in CSF (F = 9.82, p<0.0001) and serum (F = 4.62, p = 0.0085).
The highest values of AEA in CSF were found in dogs with Intraspinal Spirocercosis and
differed significantly with all other groups SRMA A (p = 0.0084), SRMA Tr (p<0.0001) and
healthy dogs (p = 0.0001). Levels of AEA in CSF were significantly increased in SRMA A com-
pared to SRMA Tr (p = 0.0482). Furthermore, healthy controls showed significantly lower
concentrations of AEA in serum in comparison to dogs with Intraspinal Spirocercosis
(p = 0.0032), SRMA A (p = 0.0111), and SRMA Tr (p = 0.0029).
Medians and ranges of AEA concentrations in CSF and serum are summarized in Table 3.
Significant differences among the groups are displayed in Fig 1.
Table 3. Levels of AEA and Total AG in CSF and serum samples analyzed: medians and ranges (minimum-maximum values).
AEA Total AG
Groups CSF (pM) Serum (nM) CSF (nM) Serum (nM)
Healthy Median 4.40 0.23 1.55 61.84
Range (1.40–6.20) (0.17–0.34) (0.88–4.35) (50.17–272.90)
SRMA A Median 5.90 0.44 2.91 193.92
Range (2.30–36.30) (0.21–0.91) (0.86–17.59) (80.39–976.15)
SRMA Tr Median 5.40 0.43 1.01 149.05
Range (1.30–10.30) (0.25–1.21) (0.26–3.91) (34.20–659.17)
Spirocercosis Median 39.40 0.69 16.13 500.10
Range (3.50–237.90) (0.41–0.84) (2.46–94.38) (186.35–827.85)
AEA: Anandamide; Total AG: 1-AG (1-arachidonoylglycerol) + 2-AG (2-arachidonoylglycerol); CSF: cerebrospinal fluid; SRMA A: steroid-responsive meningitis-
arteritis in acute stage; SRMA Tr: SRMA dogs under treatment; pM: picomolar; nM: nanomolar
https://doi.org/10.1371/journal.pone.0187197.t003
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Levels of total AG in CSF and serum
The type 3 test of fixed effects denies the hypothesis of equal means of total AG for all group
levels in CSF (F = 14.44; p<0.0001) and serum (F = 3.37; p = 0.0305).
Levels of Total AG in CSF were significantly increased in Intraspinal Spirocercosis com-
pared to SRMA A (p = 0.0072), SRMA Tr (p< 0.0001) and healthy dogs (p = 0.0005). Fur-
thermore, statistically significant differences were found between SRMA A and SRMA Tr,
Fig 1. Concentrations of AEA and Total AG in CSF and serum samples, Log to base 10. Boxes contain values from 1st to 3rd quartile, central lines inside the
boxes represent median values, and endpoints of vertical lines represent minimum and maximum values, dot (●) represent outliners. Asterisks () indicate
statistically significant differences (p<0.05). AEA: Anandamide; Total AG: 1-AG (1-arachidonoylglycerol) + 2-AG (2-arachidonoylglycerol); CSF: cerebrospinal
fluid; SRMA A: steroid-responsive meningitis-arteritis in acute stage; SRMA Tr: SRMA dogs under treatment; pM: picomolar; nM: nanomolar.
https://doi.org/10.1371/journal.pone.0187197.g001
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(p = 0.0016). Moreover, dogs suffering from SRMA in the acute phase and those with Intrasp-
inal Spirocercosis showed significantly higher concentrations of total AG than healthy controls
in serum (p = 0.0423 and p = 0.0080, respectively).
Medians and ranges of total AG concentrations in CSF and serum are summarized in
Table 3. Significant differences among the groups are displayed in Fig 1.
Spatiotemporal localization of CB2 receptors in healthy dogs
Cannabinoid receptor type 2 immunoreaction was detected in spleen and liver samples of healthy
dogs serving as positive controls. Moderate to strong immunoreaction was detected in numerous
cells of the red pulp, as well as in the periarteriolar lymphoid sheath (PALS), marginal and mantel
zone of splenic follicles (white pulp), while only few positive cells were found in the germinal cen-
ter of splenic follicles (Fig 2A and 2B). Hepatocytes as well as Kupffer cells showed strong CB2
immunoreaction, while endothelial cells showed slight immunoreaction and smooth muscle cells
of the tunica media were negative for staining with CB2 antibody (Fig 2C and 2D).
In spinal cord sections of healthy control dogs, CB2 was moderately to strongly expressed
in numerous small vesicles in the cell membrane by approximately 90% of glial cells which
were homogeneously distributed throughout the grey and white matter (Fig 3D and 3G).
Moreover, slight to moderate immunoreaction was present in the cytoplasma of neurons in
the ventral and dorsal horns. No CB2 immunoreaction was detectable in the tunica media and
interna of blood vessels. Similarly, endothelial cells, flat mesothelial-like arachnoid membrane
cells and pia mater cells lacked CB2 expression in the healthy state (Fig 3A).
Spatiotemporal localization of CB2 receptors in SRMA lesions
In cervical, thoracic, and lumbar spinal cord sections of dogs with SRMA, a constant finding in
all examined dogs, was strong CB2 expression on infiltrating leukocytes (i.e. lymphocytes,
plasma cells, neutrophils, and macrophages). In most dogs, inflammatory infiltrates were found
within the adventitia of vessels, perivascular, subdural, and subarachnoidal, but in few dogs
inflammatory cells were found within the white and grey matter (Fig 4A, 4B, 4C and 4D). Most
vessels of the SRMA dogs showed thickened walls with a subendothelial spindle cell and collagen
intimal proliferation which remained devoid of CB2 immunoreactivity. Endothelial cells lacked
CB2 immunoreaction except rare scattered CB2 positive single cells. Slight to moderate CB2
immunoreactivity was observed in smooth muscle cells in the tunica media of medium to large
caliber arteries (Fig 4A and 4B). Additionally, different CB2 immunoreaction patterns were
identified in the spinal cords: on the one side, moderate, diffuse, homogeneous staining of the
white matter (not shown), on the other side, negative staining of white matter areas with con-
trasting strong CB2-positive glial cells (Fig 3E). Moreover, the morphology of glial cells that
labelled with CB2 antibody varied between sections. In some sections, mainly ramified glial cells
(50–90%), presumably astrocytes, demonstrated a moderate to strong CB2-immunoreaction
both in the grey and white matter which was comparable to healthy controls (Fig 3E and 3H). In
contrast, in other sections, CB2 was strongly expressed by small round glial cells (10–50%), pre-
sumably oligodendrocytes, within the white and grey matter. Generally, neurons of the dorsal
and ventral horns within the grey matter showed inhomogeneous spotted slight to strong cyto-
plasmic CB2 immunoreactivity (Fig 3H). Notably, also moderate to strong CB2-positive arach-
noid mesothelial-like cells as well as pia mater cells near the lesions were present (Fig 3B).
Spatiotemporal localization of CB2 receptors in IS lesions
On thoracic spinal cord sections of dogs with IS, strong CB2 expressing leucocytes, predomi-
nantly lymphocytes, plasma cells and macrophages but also eosinophils and neutrophils were
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found adjacent to the parasite or the parasite tracts, accompanied by severe, multifocal to coa-
lescing necrosis and hemorrhage but also within the subarachnoidal space (Fig 5B, 5C and
5D). Scattered glial cells stained moderately to strongly positive near the lesions and obtained
a round-shaped morphology (Fig 3F), while glial cells in the white and grey matter distant
from the lesion expressed low CB2 immunoreaction. Interestingly, moderate to severe axonal
degeneration was found in the white matter with swollen CB2 positive axons (spheroids) and
marked dilation of myelin sheets (Fig 5A). Neurons showed inhomogeneous moderate to
strong cytoplasmic immunoreactivity within the dorsal and ventral horns (Fig 3I). Endothelial
cells within the white and grey matter, but also in the subarachnoidal space showed slight cyto-
plasmic immunoreaction (Fig 3C).
Fig 2. CB2 immunoreaction in spleen and liver of a healthy control dog. A) CB2 is expressed in numerous leukocytes in the marginal
zone (macrophages, dendritic cells, transit B and T cells) and mantel zone (T cells) of splenic follicle (white pulp) whereas few positive cells
are seen in the germinal center (B Cells). B) Insert/Close up of the marginal and mantel zone of splenic follicle showing numerous CB2
positive leukocytes (arrow). C) CB2 is abundantly expressed in hepatocytes and Kupffer cells as well as slightly in endothelial cells while
tunica media and adventitia remain negative. D) Insert depicting CB2 positive Hepatocytes and Kupffer cells. G: Germinal center; MZ:
mantel zone; MarZ: marginal zone. IHC was performed using the avidin-biotin-peroxidase complex (ABC) method.
https://doi.org/10.1371/journal.pone.0187197.g002
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A semi quantitative analysis of the CB2 immunoreaction in the spinal cord of dogs with
SRMA, IS and healthy controls at the cellular level is summarized in Fig 6.
Discussion
In the present study, it could be proven that the endocannabinoid system is involved in two
different canine inflammatory CNS diseases.
Fig 3. CB2 immunoreaction in spinal cord sections of dogs with SRMA, IS and healthy controls. A) Detail of blood vessel and meninges of a healthy dog, notice lack
of immunoreaction in the adventitia, endothelial cells, flat mesothelial-like arachnoid membrane cells and pia matter cells. B) Blood vessel of a dog with SRMA
characterized by strong perivascular and subarachnoidal CB2 positive inflammatory infiltrates and slight to moderate CB2 immunoreaction within the smooth muscle
cells of the tunica media. C) Blood vessel of a dog with IS, slight CB2 immunoreactivity is seen in the tunica media of the vessel whereas perivascular inflammatory
infiltrates show strong immunoreaction. D) Detail of glial cells in the white mater of a healthy dog with moderate to strong intracytoplasmic CB2 immunoreaction. E)
Strong CB2 immunostaining is shown in round glial cells within the white matter of a dog with SRMA. F) Strong CB2 immunoreaction in astrocytes within the white
matter of a dog with IS. G) Moderate to strong immunolabeling of astrocytes and slight immunolabeling of neurons with CB2 antibody within the grey matter of a
healthy dog. H) Moderate CB2 immunostaining is shown in the cytoplasm of a neuron and adjacent glial cells within the grey matter of a dog with SRMA. I) Strong
spotted CB2 immunoreaction in the cytoplasm of neurons within the grey matter of a dog with IS. IHC was performed using the avidin-biotin-peroxidase complex
(ABC) method.
https://doi.org/10.1371/journal.pone.0187197.g003
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In the last decades, evidence has shown that the functions of the endocannabinoid system
are not limited to the CNS but are involved in the whole organism of mammals [42]. Although
the endocannabinoid system has been widely studied for its involvement in regulation of neu-
rotransmission [6, 43, 44], increasing evidence supports its involvement in immunomodula-
tion [5, 15, 18, 19, 23, 25] and neuroprotection [45–47]. CB receptors are expressed by
leukocytes [14, 20], mice with deficient CB receptors display an altered, usually more severe,
inflammatory phenotype [18]. Therefore, the enhancement of the endocannabinoids or the
activation of cannabinoid receptors may have valuable therapeutic effects [48].
In accordance with previous studies in other species [39, 49, 50] and in dogs [34], overall
CSF levels of AEA were in the picomolar range (pM) and of total AG in nanomolar range
(nM). Levels of 2-AG in unstimulated tissues and cells are usually much higher than those of
AEA, and are in principle sufficient to permanently activate both cannabinoid receptors [11,
51]. Interestingly, 2-AG spontaneously isomerizes to its biologically inactive form 1-AG, by
acyl migration [39]. This phenomenon is of particular importance for quantification of 2-AG.
Therefore, both 1-AG and 2-AG were measured and summarized to total AG, since such cal-
culation has been proven to be more accurate [39].
Fig 4. Immunohistochemistry of anti-CB2 antibody in spinal cord SRMA lesions. A) Strong CB2 positive perivascular inflammatory
infiltrates surrounding meningeal blood vessels. B) The CB2 positive leukocyte population mainly consists of lymphocytes, plasma cells and
fewer macrophages. C) Severe diffuse infiltration of the dura mater with CB2 positive inflammatory cells. D) Vacuolization of white matter
areas with concomitant CB2 positive glial cells and leukocytes. IHC was performed using the avidin-biotin-peroxidase complex (ABC) method.
https://doi.org/10.1371/journal.pone.0187197.g004
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The highest levels of AEA and total AG in CSF were found in dogs with Intraspinal Spiro-
cercosis and differed significantly from all other groups. High values occurred also in SRMA A
group that showed significantly higher levels of both AEA and total AG compared to SRMA
Tr. Spirocercosis in dogs has been mostly associated with the presence of esophageal granulo-
mas [52], and although the disease is frequently subclinical, esophageal dysphagia is consid-
ered the clinical hallmark [52]. Aberrant migration of the worm to unusual anatomical
structures results in atypical clinical signs [28]. Neurological deficits presented in the IS group
are similar to previous findings of extradural and intraspinal Spirocerca lupi migration [30, 53].
Although the reason for aberrant migration is still unclear [28], it possibly occurs via the inter-
costal arteries, originating from the thoracic aorta, through their spinal branches and into the
extradural space [53]. The worm possibly penetrates the dura and pia mater to enter the spinal
cord parenchyma [29]. Eosinophils play a major role in dealing with elimination of parasites
[54]. CSF samples from the IS group showed mixed neutrophilic pleocytosis with moderate to
severe eosinophilia and foamy macrophages. CSF findings agree with previous CSF analysis in
Fig 5. Immunohistochemistry of anti-CB2 antibody in spinal cord lesions of dogs with intraspinal spirocercosis. A) Notice moderate to strong
CB2 immunostaining of swollen axons (spheroids) within the white matter. B) Prominent intracytoplasmic staining of large foamy macrophages
(gitter cells) with CB2 antibody. C) Severe diffuse infiltration of the subarachnoidal space with strongly CB2 labeled inflammatory cells. D) The
CB2 positive leukocyte population mainly consists of macrophages and fewer lymphocytes and plasma cells. IHC was performed using the avidin-
biotin-peroxidase complex (ABC) method.
https://doi.org/10.1371/journal.pone.0187197.g005
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single cases of dogs with intraspinal migration [29, 55]. This disease was chosen for the current
study, to include a canine population with inflammatory CNS disease and eospinophilia in
CSF samples to compare with SRMA dogs and a clear neutrophilic pleocytosis. All CSF sam-
ples in the SRMA A group displayed a neutrophilic pleocytosis, the key feature of the acute
stage of SRMA [32, 56, 57].
ECs are lipids that are able to modulate cell migration through specific receptors [1]. Both
in vitro and in vivo studies have shown CB2 receptor involvement in eosinophil migration [1],
which is supported by the current study. Human peripheral eosinophils express functional
CB2 receptors that mediate chemotaxis towards 2-AG, but not AEA [58]. Interestingly,
another study showed that 2-AG induces migration of eosinophils in a dose-dependent man-
ner and that the concentration required appears to be pathophysiologically relevant [59]. Since
2-AG is a fully effective CB2 agonist [60], several studies have focused on the immunomodula-
tory effects of 2-AG, while information of AEA in this aspect is lacking. Moreover, 2-AG has
been proven to be produced and released from platelets [61], macrophages [61, 62], endothelial
cells [63, 64], glial cells [65], macrophages [62] and adipocytes [66]. The main 2-AG effects on
neutrophils seem to be independent of CB activation in humans [67]. Although 2-AG does not
seem to have a chemotactive effect on neutrophils, it has been proven to activate them [67].
Fig 6. CB2 immunoreaction in the spinal cord of dogs with SRMA, IS and healthy controls. SRMA: steroid-responsive meningitis-arteritis; IS: intraspinal
spirocercosis. Intensity: no, low, moderate, high. Quantity: -, no; +,< 10%; ++, 10–50%; +++, 50–90%, and ++++,>90% immunopositive cells; n.a. not applicable.
https://doi.org/10.1371/journal.pone.0187197.g006
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CSF levels of AEA and 2-AG in healthy dogs were low as already determined in previous
measurements [34]. Such low values were also found in dogs under treatment with glucocorti-
costeroids (SRMA Tr group). Increased levels of AEA have been found in CSF in dogs with
epilepsy and correlated with disease severity and duration [34]. AEA seems to regulate seizure
threshold in epilepsy [34]. AEA is a high affinity ligand for CB1 receptors [60], mostly
expressed in CNS tissue and regulating neurotransmission [68]. AEA CSF levels in SRMA
were much higher than in dogs with epilepsy. 2-AG is the fully effective CB2 agonist [60], but
AEA has been linked to activate CB2 receptors in pathological conditions [69] and could
enhance or regulate the fulminant inflammatory response in SRMA.
AEA concentration in serum was significantly higher in all groups (Intraspinal Spirocerco-
sis, SRMA A, and SRMA Tr) compared to healthy controls. Moreover, dogs suffering from
SRMA in the acute phase and those with Intraspinal Spirocercosis showed significantly higher
concentrations of total AG than healthy controls in serum. SRMA is a systemic immune-medi-
ated disorder [32]. Even when the main lesions are found in the cervical leptomeninges,
SRMA causes systemic inflammatory lesions of the vessels of the heart and intestine [70, 71].
Albeit migration and persistence of larvae or adult worms are responsible for intraspinal
lesions in Spirocercosis [72], the tissue damage is not restricted to the spinal cord in these
dogs. The systemic nature of both diseases might explain the increased levels of both ECs in
serum.
Strong CB2 immunoreaction was found in leukocytes within the marginal zone of splenic
follicles and hepatocytes and Kupffer cells as previously described [20, 73, 74]. Previous studies
performed in healthy dog tissues have shown strong CB2 immunoreaction in B cell zones of
lymphoid follicles, and diffuse immunoreaction in cells in the dermis, including perivascular
cells with mast cell morphology, fibroblasts, and endothelial cells [75]. There is however a lack
of studies describing CB2 receptor expression in the CNS of dogs. Our study showed moderate
to strong CB2 expression on more than 90% ramified glial cells within the grey and white mat-
ter of the cervical spinal cord sections of healthy dogs. Moreover, slight to moderate immunor-
eaction was found in the neurons in the ventral and dorsal horns. CB2 receptor expression,
was initially thought to occur only in peripheral tissues (mostly immune organs and cells) [1,
3, 14, 20]. However, several studies have demonstrated CB2 expression in microglia [76–79],
oligodendrocytes, astrocytes and endothelial cells in the healthy CNS [80–83]. The expression
of CB2 receptors in neurons remains controversial [84]. Nonetheless, functional CB2 receptors
have been found in neuronal subpopulations in cerebellum, brainstem, cerebral cortex [85–
88], although less concentrated than CB1 receptors [85]. In SRMA and IS CB2 expression
seemed to be upregulated both in glial cells and neurons. However, CB2 expression depended
on lesion severity and was even downregulated in glial cells in regions with severe necrosis and
cell loss. Interestingly, CB2 positive glial cells underwent changes in the morphology in SRMA
and IS toward a round morphology showing less and shorter cytoplasmic extensions. Although
further studies are needed to exactly confirm the type of glial cells expressing CB2, it might be
speculated that the change in morphology is a consequence of astrogliosis and/or correlated
with the occurrence of activated microglia. In other studies, upregulation of CB2 receptor
expression in microglia, macrophages, neurons and astrocytes upon activation has been dem-
onstrated [5, 86, 89, 90]. An increased production of AEA and 2-AG has also been described
in several other pathologies of the CNS [48, 91, 92]. The understanding of the role of AEA in
inflammation is particularly important regarding its interaction with microglia [93]. Depend-
ing on the relative quantities of 2-AG and AEA that accumulate in certain CNS areas, their
competition at CB2 receptors may determine the extent to which CB2 receptors will regulate
microglial cell behavior and phenotype, towards a M1 pro-inflammatory phenotype or a M2
anti-inflammatory phenotype [93]. Indeed, CB2 can be induced on demand during early
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inflammatory events and it has been linked to attenuation of pro-inflammatory cytokine pro-
duction by microglia, counteracting neuronal damage [1, 42]. On the other hand, upon CB2
activation microglia have also been shown to cause pro-inflammatory actions by eliciting cell
migration [65].
CB2 was strongly expressed on infiltrating leukocytes (i.e. neutrophils, lymphocytes, plasma
cells, eosinophils and macrophages) in spinal cord lesions of dogs with SRMA and IS. Interest-
ingly, arachnoid mesothelial-like cells and cells in the pia matter near the lesions expressed
also CB2. Immune cells express high levels of CB2, and even a hierarchy of CB2 receptor
expression has been described within the immune system (B cells > natural killer
cells >monocytes > neutrophils > CD8 lymphocytes > CD4 lymphocytes) [14]. The level of
expression, however, is dependent on the activation state of the cell and the type of stimuli
[20]. CB2 receptor expression in macrophages has been proven to be modulated upon activa-
tion. CB2 is detected at low levels in resting cells, while it is present at high levels in activated
macrophages [5, 89].
Endocannabinoids have been shown to downregulate inflammation in numerous experi-
mental models [20–26]. Activation of the cannabinoid system has been linked to decreased
inflammatory cell recruitment and enhanced anti-inflammatory cytokine production [18].
Evidence shows that exogenous application of AEA and 2-AG exerts anti-inflammatory effects
by decreasing the production of inflammatory mediators [19]. Interestingly, increased levels of
AEA and 2-AG have been found in the spinal cord of rats after moderate-severe spinal cord
injury (SCI) [48, 94]. The rapid activation of cannabinoid receptors by endocannabinoids after
SCI is thought to be an endogenous protective response [48]. In another study, Arevalo-Martin
and colleagues showed that one single injection of 2-AG 30 minutes after the induction of the
lesion, protects the white matter from secondary damage, reducing the lesion expansion and
myelin loss [46], while CB1 and CB2 antagonists increased myelin damage [48]. Strikingly,
administration of CB1 and CB2 antagonists impaired the spontaneous motor recovery
observed in rats after SCI [48].
Although several studies support endocannabinoids as anti-inflammatory mediators, sev-
eral in vitro and in vivo experiments have reported a pro-inflammatory role of the endocanna-
binoid system in the development of inflammation [18]. These pro-inflammatory effects have
been associated with enhanced leukocyte recruitment and activation, production of reactive
oxygen species and release of pro-inflammatory cytokines [1, 58, 59, 65, 95, 96]. Nonetheless,
most of these pro-inflammatory effects attributed to endocannabinoids involve 2-AG, but not
AEA [18]. Indeed, AEA is a potent anti-inflammatory endocannabinoid and acts practically
on all cell subsets except natural killer cells and B cells, while 2-AG exerts both pro- and anti-
inflammatory effects which seem to be strictly dependent on cell type [97]. The anti-inflamma-
tory effects of AEA may explain the fact that in SRMA Tr AEA serum levels remained high,
while the pro-inflammatory total AG levels decreased notably in serum in the SRMA Tr
group.
The endocannabinoid system response in inflammation is indeed dependent on type and
state of the disease. While CB2 receptor activation in general mediates immunosuppressive
effects limiting inflammation and being associated with tissue damage in several pathological
conditions, in some disease states activation of the CB2 receptor may enhance or even trigger
tissue damage [84]. In physiological conditions, the endocannabinoid production by neurons
is high and in microglia low [98]. In diseased CNS tissue with an activated immune system the
cell-specific expression profile of cannabinoid receptors changes, resulting in higher expres-
sion of CB2 receptors in activated microglia [16, 98], which can secondarily activate astrocytes
leading to further induction of expression of inflammatory factors [5]. Such an upregulation
on activated microglia cells was also seen in the evaluated canine inflammatory CNS diseases
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and could be the reason for the excessive immune response in SRMA. As the disorder pro-
gresses, the blood brain barrier (BBB) becomes partially disrupted and blood macrophages, B
cells, T cells, natural killer cells and other infiltrating leukocytes start upregulating CB2 [5, 42,
93]. The activation of the receptors further stimulates the migration and/or activation of these
cells into the nervous tissue and towards the endocannabinoids produced by microglia, neu-
rons [42] and leukocytes [61, 62, 98], which might explain eosinophilia in CSF samples of IS
dogs in the current study after extremely high endocannabinoid levels.
Although the initial enhancement of the endocannabinoid system has been proven to have
an endogenous protective response and attempts to control inflammation, as the disease pro-
gresses, a later dysregulation of the endocannabinoid system during neuroinflammation leads
to increased CB2 receptor expression, excessive endocannabinoid production leading to an
exacerbated inflammatory response. Thus, both CB2 agonists and antagonists might be benefi-
cial in counteracting the inflammatory consequences depending on the disease phase [42].
Increased AEA, total AG and upregulation of CB2 receptors might therefore explain the wax-
ing and waning course of SRMA.
Conclusions
The present study revealed an upregulated endocannabinoid system in canines with inflamma-
tory CNS diseases, highlighting the endocannabinoid system as a potential target for treatment
of inflammatory CNS diseases. Levels of ECs in CSF of dogs with inflammatory CNS diseases
were increased compared with healthy dogs, and those under treatment. Furthermore, dogs
with eosinophilic pleocytosis showed higher level of ECs than those with neutrophilic pleocy-
tosis. Such pleocytosis could be due to the effects of ECs on eosinophil migration to the CSF.
We also found upregulated expression of CB2 receptors in SRMA and IS lesions. Such an upre-
gulation of AEA and 2-AG together with an overexpression of CB2 receptors may indicate a
dysregulation of the endocannabinoid system and may be involved in the inflammatory
response. Therefore, the development of new anti-inflammatory treatment strategies in canine
CNS inflammation should involve the EC system.
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